US Patent

US12409180 — Formulation production process

Formulation · Assigned to Verona Pharma Ltd · Expires 2043-02-20 · 17y remaining

Vulnerability score 55/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a process for producing a sterile liquid pharmaceutical composition suitable for inhalation that contains ensifentrine particles.

USPTO Abstract

The present invention relates to a process for producing a sterile liquid pharmaceutical composition suitable for administration by inhalation comprising ensifentrine particles, wherein the process comprises: (a) heating ensifentrine particles at a temperature of from 100° C. to 220° C. to obtain sterile ensifentrine particles; and (b) combining the sterile ensifentrine particles with a sterile liquid vehicle to produce the sterile liquid pharmaceutical composition suitable for administration by inhalation. A process for producing an ampule comprising the sterile liquid pharmaceutical composition is also described.

Drugs covered by this patent

Patent Metadata

Patent number
US12409180
Jurisdiction
US
Classification
Formulation
Expires
2043-02-20
Drug substance claim
No
Drug product claim
Yes
Assignee
Verona Pharma Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.